Stephen N. J. Korsman

Stephen N. J. Korsman

Auto-generated profile, based on publicly available information

Stephen N. J. Korsman

University of Cape Town

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DHDiana Hardie
Diana Hardie
SKStephen Korsman
Stephen Korsman
SASharifa Ameer
Sharifa Ameer
LVLara Vojnov
Lara Vojnov
NHNei-Yuan Hsiao
Nei-Yuan Hsiao
Viral load testing is key to monitoring response to anti-retroviral therapy (ART). However, in lower and middle income countries with large epidemics, pre-analytical challenges threaten the quality of testing. It is unknown how much delayed processing and adverse storage affects the validity of results. The aim of this study was to determine the impact of delayed testing and warmer storage conditions on HIV RNA stability in diagnostic samples. 1194 samples, collected in EDTA or plasma preparation (PPT) tubes, were studied. Immediately after initial testing, primary tubes were stored for 72, 96 or 168 hours at 4°C, 20°C or 30°C. The viral load was then repeated and the 2 results were compared. Viral loads were very stable, with <0.5 log copies/ml median difference noted between paired tests for all storage times and temperatures. The viral load in samples stored for up to a week reliably differentiated between ART-suppressed and failing patients in 98.83% of instances. However, re-centrifugation immediately prior to repeat testing was essential to avoid falsely elevated readings, probably due to contamination of plasma with cell-associated viral nucleic acids. Approximately 20% of samples with initially undetectable viral loads were weakly positive (<100 copies/mL) on repeat. This was not exacerbated by duration or temperature of storage. Viral RNA in diagnostic samples is stable well beyond currently recommended limits. However, when testing stored primary samples, contamination of plasma with cellular material easily occurs. Low viral loads (<100copies/mL) in samples stored in this way should be interpreted with caution.

11 January 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MLMichael A. Linström
Michael A. Linström
WPWolfgang Preiser
Wolfgang Preiser
NNNokwazi N. Nkosi
Nokwazi N. Nkosi
HVHelena W. Vreede
Helena W. Vreede
SKStephen N. J. Korsman
Stephen N. J. Korsman
GZGert van Zyl
Gert van Zyl
Automated testing of HIV serology on clinical chemistry analysers has become common. High sample throughput, high HIV prevalence and instrument design could all contribute to sample cross-contamination by microscopic droplet carry-over from seropositive samples to seronegative samples resulting in false positive low-reactive results. Following installation of an automated shared platform at our public health laboratory, we noted an increase in low reactive and false positive results. Subsequently, we investigated HIV serology screening test results for a period of 21 months. Of 485 initially low positive or equivocal samples 411 (85%) tested negative when retested using an independently collected sample. As creatinine is commonly requested with HIV screening, we used it as a proxy for concomitant clinical chemistry testing, indicating that a sample had likely been tested on a shared high-throughput instrument. The contamination risk was stratified between samples passing the clinical chemistry module first versus samples bypassing it. The odds ratio for a false positive HIV serology result was 4.1 (95% CI: 1.69–9.97) when creatinine level was determined first, versus not, on the same sample, suggesting contamination on the chemistry analyser. We subsequently issued a notice to obtain dedicated samples for HIV serology and added a suffix to the specimen identifier which restricted testing to a dedicated instrument. Low positive and false positive rates were determined before and after these interventions. Based on measured rates in low positive samples we estimate that before the intervention, of 44 117 HIV screening serology samples, 753 (1.71%) were false positive, declining to 48 of 7 072 samples (0.68%) post-intervention (p<0.01). Our findings showed that automated high throughput shared diagnostic platforms are at risk of generating false-positive HIV test results, due to sample contamination and that measures are required to address this. Restricting HIV serology samples to a dedicated platform resolved this problem.

1 January 2025 in Southern African Journal of HIV Medicine
Verified
Journal Article
Open access
PDF file
NONatasha L. O'COnnell
Natasha L. O'COnnell
TMTara-Lee von Mollendorff
Tara-Lee von Mollendorff
GZGert van Zyl
Gert van Zyl
SKStephen Korsman
Stephen Korsman
JNJames Nuttall
James Nuttall
Dolutegravir resistance is predominantly reported in antiretroviral therapy-experienced individuals. We describe an infant who developed high-level resistance to abacavir, lamivudine, and dolutegravir within 97 days of initiation, despite initial wild-type infection. Causative factors likely include probable sub-therapeutic antiretroviral drug levels, poor tolerance, severe immunocompromise, and a high pre-treatment viral load. What this study adds: The evolution of DTG resistance from a confirmed transmitted wild-type virus in this infant is more rapid than previously described. Identification of risk factors for developing DTG resistance in infants requires further investigation.

22 December 2023 in African Journal of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
DHDiana Hardie
Diana Hardie
HNHoward Newman
Howard Newman
JRJoanna Reid
Joanna Reid
NHNei-Yuan Hsiao
Nei-Yuan Hsiao
GZGert van Zyl
Gert van Zyl
SKStephen Korsman
Stephen Korsman
Background: Understanding factors that impact HIV viral load (VL) accuracy in resource-limited settings is key to quality improvement. Objective: We evaluated whether testing delay and specimen storage between 25 °C and 30 °C before testing affected results. Methods: Between November 2019 and June 2023, 249 individuals on antiretroviral therapy, or with newly diagnosed HIV, were recruited from clinics in Cape Town and Gqeberha, South Africa, and three plasma preparation tubes were collected. One tube was tested within 24 h, while the others were stored uncentrifuged at ambient temperatures before testing. Centrifugation and testing of matched samples were performed on Day 4 and Day 7 after collection. Results: Time delay and ambient storage had minimal impact in specimens with a Day 1 VL of > 100 copies/mL. When grouped by Day 1 VL range, 96% – 100% of specimens at Day 4 and 93% – 100% at Day 7 had VLs within 0.5 log copies/mL of the first result. The greatest variability at Days 4 and 7 was observed when the Day 1 VL was < 100 copies/mL. However, there was no trend of increasing difference over time. Of Day 1 specimens with undetectable VL, or VL < 50 copies/mL, 80% had concordant results at Day 4 and 78% at Day 7. Conclusion: These results show that VL is stable in plasma preparation tubes for 7 days when stored at room temperature. There is significant variability in specimens with low VL, but variability is not affected by testing delay. What this study adds: Ideal HIV VL testing conditions are frequently unachievable in resource-limited settings. Data are needed on whether this impacts on the validity of test results. Our results provide reassurance that storage at ambient temperature for up to 7 days before testing does not substantially affect the VL result.

1 January 2012
Verified
Book Chapter
Closed access
SKStephen N.J. Korsman
Stephen N.J. Korsman
GZGert van Zyl
Gert van Zyl
LNLouise Nutt
Louise Nutt
MAMonique I. Andersson
Monique I. Andersson
Wolfgang PreiserWolfgang Preiser
Wolfgang Preiser

1 January 2012
Verified
Book Chapter
Closed access
SKStephen N.J. Korsman
Stephen N.J. Korsman
GZGert van Zyl
Gert van Zyl
LNLouise Nutt
Louise Nutt
MAMonique I. Andersson
Monique I. Andersson
Wolfgang PreiserWolfgang Preiser
Wolfgang Preiser